Treatment of multiple sclerosis—success from bench to bedside
M Tintore, A Vidal-Jordana… - Nature Reviews …, 2019 - nature.com
The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
Reassessing B cell contributions in multiple sclerosis
There is growing recognition that B cell contributions to normal immune responses extend
well beyond their potential to become antibody-producing cells, including roles at the innate …
well beyond their potential to become antibody-producing cells, including roles at the innate …
Neurological immunotherapy in the era of COVID-19—looking for consensus in the literature
C Korsukewitz, SW Reddel, A Bar-Or… - Nature reviews …, 2020 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with
neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains …
neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains …
Abnormal B-cell and Tfh-cell profiles in patients with Parkinson disease: a cross-sectional study
Background and Objectives There has been growing interest in potential roles of the
immune system in the pathogenesis of Parkinson disease (PD). The aim of the current study …
immune system in the pathogenesis of Parkinson disease (PD). The aim of the current study …
S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes
D Dixit, VM Hallisey, EYS Zhu… - The Journal of …, 2024 - Am Soc Clin Investig
Effective immunity requires a large, diverse naive T cell repertoire circulating among
lymphoid organs in search of antigen. Sphingosine 1-phosphate (S1P) and its receptor …
lymphoid organs in search of antigen. Sphingosine 1-phosphate (S1P) and its receptor …
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19
C Valencia-Sanchez, DM Wingerchuk - Multiple sclerosis and related …, 2020 - Elsevier
Background Treatment decisions in patients with multiple sclerosis (MS) during the
coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether …
coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether …
Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis
Biomarkers predicting fingolimod (FTY) treatment response in relapsing-remitting multiple
sclerosis (RRMS) are lacking. Here, we performed extensive functional immunophenotyping …
sclerosis (RRMS) are lacking. Here, we performed extensive functional immunophenotyping …
Lessons from S1P receptor targeting in multiple sclerosis
Abstract Sphingosine 1-phosphate (S1P) is a potent bioactive sphingolipid binding to
specific G protein-coupled receptors expressed in several organs. The relevance of S1P …
specific G protein-coupled receptors expressed in several organs. The relevance of S1P …
Influence of previous disease-modifying drug exposure on T-lymphocyte dynamic in patients with multiple sclerosis treated with ocrelizumab
D Landi, A Grimaldi, F Bovis, M Ponzano… - Neurology …, 2022 - AAN Enterprises
Background and Objectives To investigate the longitudinal dynamic of lymphocyte subsets
during treatment with ocrelizumab (OCR) in patients with multiple sclerosis (PwMS) …
during treatment with ocrelizumab (OCR) in patients with multiple sclerosis (PwMS) …
Secondary immunodeficiency and risk of infection following immune therapies in neurology
Secondary immunodeficiencies (SIDs) are acquired conditions that may occur as sequelae
of immune therapy. In recent years a number of disease-modifying therapies (DMTs) has …
of immune therapy. In recent years a number of disease-modifying therapies (DMTs) has …